patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · antibody
KESIMPTA
Marketedupdated 2mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 17 investigational indications.
targets
B-lymphocyte antigen CD20
all catalysts(13)
approval · 13
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that